AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
出版年份 2014 全文链接
标题
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
作者
关键词
Melanoma, Aurora A kinase, Targeted therapy, Combined therapy, 3D-human skin reconstruction model
出版物
Journal of Translational Medicine
Volume 12, Issue 1, Pages -
出版商
Springer Nature
发表日期
2014-07-30
DOI
10.1186/s12967-014-0216-z
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The role of MEK inhibitors in the treatment of metastatic melanoma
- (2014) Antonio M. Grimaldi et al. CURRENT OPINION IN ONCOLOGY
- Analysis of the BRAF V600E mutation in primary cutaneous melanoma
- (2014) J.S.S. Inumaru et al. GENETICS AND MOLECULAR RESEARCH
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- (2014) Grant A McArthur et al. LANCET ONCOLOGY
- BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAF V600E metastatic melanoma
- (2013) J S Wilmott et al. BRITISH JOURNAL OF CANCER
- Activities of multiple cancer-related pathways are associated withBRAFmutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells
- (2013) Dingxie Liu et al. CELL CYCLE
- Treatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other Therapies
- (2013) S Jang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors
- (2013) Karen E. Sheppard et al. EUROPEAN JOURNAL OF CANCER
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
- (2013) Paolo A. Ascierto et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma
- (2013) Kerstin Trunzer et al. JOURNAL OF CLINICAL ONCOLOGY
- TGF-β1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction
- (2013) V Tirino et al. Cell Death & Disease
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- Aurora A kinase (AURKA) in normal and pathological cell division
- (2012) Anna S. Nikonova et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence
- (2012) Yan Liu et al. EMBO Molecular Medicine
- BRAF/NRASMutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
- (2012) Maria Colombino et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With MetastaticBRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
- (2012) Kevin B. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- MAP kinase signaling and inhibition in melanoma
- (2012) R J Sullivan et al. ONCOGENE
- Translationale Forschung und Diagnostik beim Melanom
- (2012) J. Rüschoff et al. PATHOLOGE
- Comparative Analysis of Dynamic Cell Viability, Migration and Invasion Assessments by Novel Real-Time Technology and Classic Endpoint Assays
- (2012) Ridha Limame et al. PLoS One
- Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma
- (2011) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epithelial to Mesenchymal Transition by TGFβ-1 Induction Increases Stemness Characteristics in Primary Non Small Cell Lung Cancer Cell Line
- (2011) Giuseppe Pirozzi et al. PLoS One
- Cancer Statistics, 2009
- (2009) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Expression of Aurora A (but Not Aurora B) Is Predictive of Survival in Breast Cancer
- (2008) Y. Nadler et al. CLINICAL CANCER RESEARCH
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started